-1 of 2- 18 May 2016 21:00:00 UTC Press Release: Novartis to present pivotal data in hematologic and solid tumor cancers at 2016 ASCO Annual Meeting Novartis International AG / Novartis to present pivotal data in hematologic and solid tumor cancers at 2016 ASCO Annual...
-1 of 2- 18 May 2016 21:00:00 UTC Press Release: Novartis to present pivotal data in hematologic and solid tumor cancers at 2016 ASCO Annual Meeting Novartis International AG / Novartis to present pivotal data in hematologic and solid tumor cancers at 2016 ASCO Annual...
New York, May 18, 2016 -- Issue: School Building Refunding Revenue Bonds - Series of 2016; Rating: Aa3; Rating Type: Enhanced LT; Sale Amount: $5,485,000; Expected Sale Date: 05/19/2016; Rating Description: Lease Rental: Appropriation;
New York, May 18, 2016 -- Issue: School Building Refunding Revenue Bonds, Series of 2016; Rating: Aa3; Rating Type: Enhanced LT; Sale Amount: $2,110,000; Expected Sale Date: 05/24/2016; Rating Description: Lease Rental: Appropriation;
Novartis International AG / Novartis to present pivotal data in hematologic and solid tumor cancers at 2016 ASCO Annual Meeting . Processed and transmitted by Nasdaq OMX Corporate Solutions. The issuer is solely responsible for the content of...
NovoCure (NASDAQ: NVCR) announced today that a new subgroup analysis of its ongoing phase 2 pilot PANOVA clinical trial will be presented at the ...
New York, May 18, 2016 -- Summary Rating RationaleVollständigen Artikel bei Moodys lesen
New York, May 18, 2016 -- Issue: Energy Conservation Refunding Revenue Bonds, Series 2016; Rating: Aa3; Rating Type: Enhanced LT; Sale Amount: $2,785,000; Expected Sale Date: 05/19/2016; Rating Description: Lease Rental: Appropriation;
New York, May 18, 2016 -- Issue: School Building Refunding Revenue Bonds, Series 2016; Rating: Aa3; Rating Type: Enhanced LT; Sale Amount: $1,260,000; Expected Sale Date: 05/25/2016; Rating Description: Lease Rental: Appropriation;
Wenn sich Wirtschaftserholung fortsetzt, steigt die Wahrscheinlichkeit.
Wall Street schiebt Kurse ins Plus.
Dennoch herrscht kaum grosser Optimismus.
Der Handel mit Gütern wird weiter eingeschränkt, zudem wird dem Land der Geldhahn zugedreht.
Auch negativer Goldman-Sachs-Kommentar mahnt zur Zurückhaltung.
Experten hatten mit erneutem Rückgang gerechnet.
"Selbst die Deflationshysterie nimmt man der EZB und ihrem Chef nicht mehr ab."
Im Vorjahresvergleich gibts ein Plus von 3,1%.
Bauzulieferer steigert Umsatz nach 4 Monaten um 7,2% auf 1,5 Mrd CHF
Moscovici will jeweils ein Extra-Jahr zur Budgetsanierung einräumen. Von Bussgeldern verschont.